Pacira BioSciences
PCRX
270 hedge funds and large institutions have $1.44B invested in Pacira BioSciences in 2024 Q1 according to their latest regulatory filings, with 37 funds opening new positions, 98 increasing their positions, 84 reducing their positions, and 28 closing their positions.
32% more first-time investments, than exits
New positions opened: 37 | Existing positions closed: 28
17% more repeat investments, than reductions
Existing positions increased: 98 | Existing positions reduced: 84
3% more funds holding
Funds holding: 261 → 270 (+9)
0.19% more ownership
Funds ownership: 105.6% → 105.79% (+0.19%)
13% less capital invested
Capital invested by funds: $1.65B → $1.44B (-$217M)
20% less funds holding in top 10
Funds holding in top 10: 5 → 4 (-1)
70% less call options, than puts
Call options by funds: $4.61M | Put options by funds: $15.3M
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
ACM
Archon Capital Management
Seattle,
Washington
|
+$16.5M |
| 2 |
Pacer Advisors
Malvern,
Pennsylvania
|
+$16.3M |
| 3 |
DPCM
Doma Perpetual Capital Management
Miami,
Florida
|
+$12.2M |
| 4 |
N
Nuveen
Charlotte,
North Carolina
|
+$11.9M |
| 5 |
Marshall Wace
London,
United Kingdom
|
+$10.2M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
VPC
Vestal Point Capital
New York
|
-$34.4M |
| 2 |
Morgan Stanley
New York
|
-$21.5M |
| 3 |
RCMNY
Rubric Capital Management (New York)
New York
|
-$16.6M |
| 4 |
Federated Hermes
Pittsburgh,
Pennsylvania
|
-$8.64M |
| 5 |
BlackRock
New York
|
-$6.42M |
PCRX Hedge Fund Activity: Q1 2024 in Review
270 of the 6,942 institutional investors tracked by Wall St. Rank reported a position in Pacira BioSciences (PCRX) for Q1 2024, worth a combined $1.44B — down 13% from $1.65B a quarter earlier.
Buyers outnumbered sellers: 37 funds opened new PCRX positions and 28 closed out — a net gain of 9 holders — while 98 added to existing stakes and 84 trimmed.
The largest buyer was Archon Capital Management, opening a new position worth an estimated $16.5M. The largest seller was Vestal Point Capital, cutting an estimated $34.4M.
- 270 institutional investors held Pacira BioSciences (PCRX) as of Q1 2024, up from 261 in Q4 2023.
- Funds reported $1.44B of Pacira BioSciences stock for Q1 2024, down 13% quarter-over-quarter.
- 37 funds opened new Pacira BioSciences positions in Q1 2024 and 28 closed out, a net change of +9 holders.
- The largest Pacira BioSciences buyer in Q1 2024 was Archon Capital Management, an estimated $16.5M added.
- The largest Pacira BioSciences seller in Q1 2024 was Vestal Point Capital, an estimated $34.4M sold.
Based on aggregated 13F filings for Q1 2024.